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AB0627 RISE-SSC: A DOUBLE-BLIND, RANDOMISED STUDY EVALUATING THE EFFICACY AND SAFETY OF RIOCIGUAT FOR THE TREATMENT OF PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Background: Diffuse cutaneous systemic sclerosis (dcSSc) is a severe subtype of SSc, a rare, chronic autoimmune connective tissue disease associated with significant morbidity and mortality, and with reduced quality of life. Currently, there are no approved disease-modifying therapies to treat the vascular and fibrotic damage in patients with dcSSc. Soluble guanylate cyclase stimulators, such as riociguat, target the transforming growth factor beta pathway, inhibiting signalling through non-SMAD pathways. They have been shown to inhibit dermal fibrosis in several animal models and to ameliorate fibrosis of the skin and intestine in bleomycin-induced fibrosis and experimental chronic graft-versushost disease. 1 These preclinical data suggest that riociguat has vascular and antifibrotic properties that may be beneficial in dcSSc, potentially delaying disease progression. Objectives: RISE-SSc (NCT02283762) is an international, multicentre, randomised, double-blind, placebo-controlled, parallel-group, Phase II study to assess the efficacy and safety of treatment with riociguat versus placebo in patients with dcSSc. The primary efficacy endpoint is change in modified Rodnan skin score (mRSS) from baseline to Week 52. Methods: Eligibility criteria include a disease duration of ≤18 months and mRSS of 10-22, parameters identified to be predictors of progression of skin fibrosis. 2 Patients were randomised (1:1) to treatment with riociguat (adjusted up to 2.5 mg tid over the first 10 weeks) or placebo for a total of 52 weeks. The double-blind phase will be followed by an open-label extension phase for up to 6 years where all patients receive riociguat. Results: Study recruitment was completed on 30 Dec 2016 and 121 patients have been randomised. Mean±SD age at inclusion was 50.7±12.3 years (range 18-79) and 76% (n=92) were female. At baseline the mean±SD mRSS was 16.8±3.7 (range 10-22) and disease duration was 8.8±5.5 months (range 0.5-18.5). Almost 70% of the patients tested positive for either anti-SCL-70 (43%) or anti-RNA polymerase III (25%) antibodies, while 32% of patients tested negative for these two antibodies. Swollen and tender joint counts were present in 38 (31.4%) and 51 (42.1%) patients, respectively, while 35 patients (28.9%) had tendon friction rubs. Digital ulcers were present in 15 patients (12.4%) at baseline. Conclusions: RISE-SSc has a unique trial design with a cohort enriched for disease progressors, 2 which is reflected in the baseline characteristics of the randomised patients. Results of the RISE-SSc study will provide data to inform not only the efficacy, safety and tolerability of riociguat treatment in patients with dcSSc, but also the feasibility of a new trial design based on cohort enrichment. [1] . Digital ulcerations (DUs) are common manifestations of vascular involvement [2] . Althoughthe vascular dysfunction of SSc has been considered mainly to affect microvasculature [3] , there is recent evidence showing that SSc is associated with the prevalence of large vessel disease [4] . However, only a few studies investigated the relationship between macrovascular disease and its role in the clinical manifestations of SSc such as ulcers. PSV and RI of ulnar artery were significantly correlated with age (p=0.012 and p=0.019), disease duration (p=0.001and p=0.001) and Raynaud's phenomenon (RP) duration (p=0.048 and p=0.028). PSV and RI of tibial artery had significant correlation with age (p=0.038 and p=0.009), systolic blood pressure (p=0.022 and p=0.037) and diastolic blood pressure (p=0.015 and p=0.010).
Conclusions:
We concluded that digital ulceration in patients with SSc might be frequently related to the macrovascular dysfunction in below the elbow and knee. Background: Systemic Sclerosis (SSc) is a connective tissue disease characterized by skin fibrosis and visceral organ involvement. Localized Scleroderma (LoS), also known as morphea, is a fibrosing condition limited to the skin, subcutaneous tissue, underlying bone, and rarely central nervous system if present on face and head. SSc and LoS may share some aspects, such as histopathological findings, presence of autoantibodies and systemic symptoms, especially Raynaud phenomenon (RP). In this perspective they may represent two ends of a spectrum of disease. Objectives: The aim of our study is to evaluate the evolution from LoS to SSc in our case series of SSc patients. Methods: We retrospectively investigated 330 patients fulfilling the SSc-ACR/EULAR criteria referred to our University-based Rheumatology Unit. The occurrence of LoS preceding the SSc diagnosis was evaluated for each patient on the basis of medical records; clinical, laboratory, and instrumental features were analyzed, from the presenting symptoms at the disease onset to the first visit and during the follow-up, with particular attention to very early cutaneous manifestations. Results: Five SSc patients (1.5% of our SSc series) had a clinical history of LoS prior to SSc diagnosis. All were women with mean age at time of LoS onset of 39±16.1SD years and time interval between LoS and SSc diagnosis of 19.2±16SD months. Skin biopsy was performed in 4/5 patients showing nonspecific inflammatory infiltrate, collagen fiber deposition and dermis sclerosis. In all patients RP was the first extra-dermal symptom, preceding LoS in 2/5 patients. Cutaneous involvement was represented by patches of skin sclerosis localized in limbs, trunk and face; while scleroderma was classified as cutaneous limited SSc in 4/5 patients and sine scleroderma in one. Following the SSc onset 2/5 patients had a history of digital ulcers, 1/5 esophagopathy, 1/5 interstitial lung disease; while capillaroscopy evidenced a SSc pattern in 4/5 patients. ANA were detected in all patients with anti-ENA positivity in 3/5 (1 ACA, 1 anti-Scl70, 1 anti-U1RNP); the presence of autoantibodies was observed in 3/5 individuals before SSc onset. None referred exposure to toxics or cigarettes smoke, while autoimmune thyropathy was the most frequent comorbidity. No local treatments had been employed for LoS but only low dosage of systemic steroids. Conclusions: LoS and SSc are two distinct clinical entities that may share some clinical features; however, LoS is characterized by the absence of sclerodactyly, RP, digital ulcers, and typical SSc capillaroscopic changes; while possible internal organs involvement is much less frequently observed and the transition to SSc is exceptional and reported in only pediatric population. At our knowledge, this is the first observation of well-documented evolution from LoS to SSc in adult population as shown by updated review of the literature. The presence of RP and ANA positivity observed before the SSc onset can be considered as red flags of LoS evolution towards SSc, as reported in literature in pediatric population. SSc following LoS seems to be characterized by higher prevalence of vasculopatic symptoms compared to fibrotic complications. Finally, a careful clinical and laboratory monitoring of patients with LoS is recommendable to early identify the possible evolution to overt SSc. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5120
